This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Histomolecular Validation of [18F]-FACBC in Gliomas Using Image-Localized Biopsies
by
, , , , ,
Benedikte Emilie Vindstad
1,*,
Anne Jarstein Skjulsvik
2,3,
Lars Kjelsberg Pedersen
4,
Erik Magnus Berntsen
1,5,
Ole Skeidsvoll Solheim
6,7,
Tor Ingebrigtsen
4,8,
Ingerid Reinertsen
1,9,
Håkon Johansen
5,
Live Eikenes
1 and
Anna Maria Karlberg
1,5 1
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, 7030 Trondheim, Norway
2
Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway
3
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7030 Trondheim, Norway
4
Department of Neurosurgery, Ophthalmology and Otorhinolaryngology, University Hospital of North Norway, 9019 Tromsø, Norway
5
Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway
6
Department of Neurosurgery, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway
7
Department of Neuroscience, Norwegian University of Science and Technology, 7030 Trondheim, Norway
8
Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, 9019 Tromsø, Norway
9
Department of Health Research, SINTEF Digital, 7034 Trondheim, Norway
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(14), 2581; https://doi.org/10.3390/cancers16142581
Submission received: 27 May 2024
/
Revised: 11 July 2024
/
Accepted: 16 July 2024
/
Published: 18 July 2024
(This article belongs to the Section Methods and Technologies Development)
Simple Summary
Gliomas are the most common type of malignant brain tumors in adults. They are frequently heterogeneous, containing regions of varying properties and aggressiveness. It can be challenging to define the tumor borders and identify the most aggressive parts of the tumor based on MRI alone. This study investigates whether PET imaging with amino acid tracer [18F]-FACBC can provide additional information on the composition of the tumor. The results suggest that uptake of the tracer could be used to identify aggressive tumor tissue with high accuracy, and with higher sensitivity than that of contrast-enhanced MRI.
Abstract
Background: Gliomas have a heterogeneous nature, and identifying the most aggressive parts of the tumor and defining tumor borders are important for histomolecular diagnosis, surgical resection, and radiation therapy planning. This study evaluated [18F]-FACBC PET for glioma tissue classification. Methods: Pre-surgical [18F]-FACBC PET/MR images were used during surgery and image-localized biopsy sampling in patients with high- and low-grade glioma. TBR was compared to histomolecular results to determine optimal threshold values, sensitivity, specificity, and AUC values for the classification of tumor tissue. Additionally, PET volumes were determined in patients with glioblastoma based on the optimal threshold. [18F]-FACBC PET volumes and diagnostic accuracy were compared to ce-T1 MRI. In total, 48 biopsies from 17 patients were analyzed. Results: [18F]-FACBC had low uptake in non-glioblastoma tumors, but overall higher sensitivity and specificity for the classification of tumor tissue (0.63 and 0.57) than ce-T1 MRI (0.24 and 0.43). Additionally, [18F]-FACBC TBR was an excellent classifier for IDH1-wildtype tumor tissue (AUC: 0.83, 95% CI: 0.71–0.96). In glioblastoma patients, PET tumor volumes were on average eight times larger than ce-T1 MRI volumes and included 87.5% of tumor-positive biopsies compared to 31.5% for ce-T1 MRI. Conclusion: The addition of [18F]-FACBC PET to conventional MRI could improve tumor classification and volume delineation.
Keywords:
[18F]-FACBC; glioma; amino acid PET; MRI
